TAK-935-2002: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH DEVELOPMENTAL AND/OR EPI

Project: Research project

Project Details

StatusActive
Effective start/end date12/13/188/31/50

Funding

  • Ovid Therapeutics Inc.
  • Ovid Therapeutics Inc.